🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11352410

Anti-KK-LC-1 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11338032

Methods of preparing anti-human papillomavirus antigen T cells

THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11331385

Methods of preparing anti-human papillomavirus antigen T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11324822

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Syndax Pharmaceuticals, Inc. · Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11318211

Dosage regimes for the administration of an anti-CD19 ADC

ADC THERAPEUTICS SA · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311517

Combination of small molecule CD-47 inhibitors with other anti-cancer agents

Aurigene Discovery Technologies Limited · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11313868

Methods of detecting anti-folic acid antibodies and uses thereof

The Board of Regents of the University of Texas System · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11304935

Use of I-BRD9 or derivatives thereof in preparing anti-epileptic drugs

University of South China · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306155

Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306148

Anti-NPR1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306135

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306149

Anti-CD40 antibodies and uses thereof

CytomX Therapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299553

Anti-plasma kallikrein antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299532

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292842

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11287427

Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging

THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286305

Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleot

Dyne Therapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286290

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11279768

Anti-cancer antibodies, combination therapies, and uses thereof

PRECISION BIOLOGICS, INC. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11274149

Anti-CD100 antibodies and methods for using the same

VACCINEX, INC. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11267893

Anti-IL36R antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11267896

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254746

Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254752

Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibo

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted